You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Strides Pharma says flagship Bangalore facility gets EIR from USFDA

Capital Market 

Strides Pharma Science said its flagship facility in Bangalore received the establishment inspection report from the US drug regulator.

Strides Pharma Science's flagship facility, KRS Gardens in Bangalore, Karnataka which was inspected by the United States Food & Drug Administration (USFDA) in March 2020, has received the Establishment Inspection Report (EIR), thereby confirming the successful closure of the inspections. The announcement was made before market hours today, 26 March 2020.

On a consolidated basis, the drug maker's net profit slumped 68% to Rs 93.89 crore despite a 28.5% rise in net sales to Rs 732.44 crore in Q3 December 2019 over Q3 December 2018.

Strides Pharma Science is a global pharmaceutical company. It focuses on difficult to manufacture products that are sold in over 100 countries.

The scrip was down 0.75% at Rs 317.25. It was trading in the range of Rs 312 to Rs 346.20 so far.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, March 26 2020. 13:08 IST